Moracin M
Based on 4 publication(s) in Google Scholar
Moracin M is a phenolic component that can be isolated from Mori Cortex, is a potent phosphodiesterase-4 (PDE4) inhibitor with IC50 values of 2.9, 4.5, >40, and >100 μM for PDE4D2, PDE4B2, PDE5A1, and PDE9A2, respectively. Moracin M has anti-inflammatory activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.99%
- CAS No.: 56317-21-6
- Formule: C14H10O4
- Masse moléculaire:242.23
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Moracin M
More-
Cell Proliferation/Viability Assay
-
WB
-
RT-PCR
Voir tous les produits spécifiques à Isoform Endogenous Metabolite
More
Activité biologique
|
PDE4D2 2.9 μM (IC50) |
PDE4B2 4.5 μM (IC50) |
PDE5A1 >40 μM (IC50) |
PDE9A2 >100 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BV-2 | EC50 |
15.1 μM
Compound: moracin M
|
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated NO production after 24 hrs by Griess assay
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated NO production after 24 hrs by Griess assay
|
[PMID: 26473791] |
| C8166 | CC50 |
57.4 μg/mL
Compound: 7
|
Cytotoxicity against human C8166 cells assessed as inhibition of cell viability after 3 days by MTT assay
Cytotoxicity against human C8166 cells assessed as inhibition of cell viability after 3 days by MTT assay
|
[PMID: 23368966] |
| C8166 | EC50 |
4.59 μg/mL
Compound: 7
|
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of syncytia formation after 3 days
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of syncytia formation after 3 days
|
[PMID: 23368966] |
| Hep 3B2 | IC50 |
>30 μM
Compound: 13, Moracin M
|
Cytotoxicity against human Hep3B cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human Hep3B cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 25461329] |
| Hep 3B2 | IC50 |
>30 μM
Compound: 4
|
Inhibition of hypoxia-induced HIF1 activation in human Hep3B cells by pGL3-HRE-luciferase reporter gene assay
Inhibition of hypoxia-induced HIF1 activation in human Hep3B cells by pGL3-HRE-luciferase reporter gene assay
|
[PMID: 19072214] |
| Hep 3B2 | IC50 |
>50 μM
Compound: 4
|
Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis
Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis
|
[PMID: 19072214] |
| Hep 3B2 | IC50 |
>50 μM
Compound: 4
|
Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA
Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA
|
[PMID: 19072214] |
| HT-29 | IC50 |
73 μM
Compound: 11
|
Cytotoxicity against human HT-29 cells incubated for 24 hrs by MTT assay
Cytotoxicity against human HT-29 cells incubated for 24 hrs by MTT assay
|
[PMID: 36463729] |
Moracin M (30, 60 μM, 2h) inhibits the expression of IL-6 in A549 cells by inhibiting the activation of JNK/c-Jun. The IC50 value of Moracin M for IL-6 is 8.1 μM[1].
Moracin M inhibits the production of NO by inhibiting the expression of iNOS in alveolar macrophages (MH-S). The IC50 value of Moracin M for NO is 65.7 μM[2].
Moracin M (LPS 0.5 μg/mL, Moracin M 5-20 μM; 24h) can effectively inhibits the inflammatory response induced by lipopolysaccharide (LPS (HY-D1056)) in the intervertebral disc nucleus pulposus cell (NPCs) model, specifically by reducing the increase of inflammatory factors IL-1β, TNF-α and IL-6 [3].
Moracin M (LPS 0.5 μg/mL, Moracin M 5-20 μM; 24h) promots the autophagy and inhibits the production of inflammatory mediators in NPCs model by inhibiting the phosphorylation of PI3K and Akt [3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549 human lung epithelial cell line
-
Concentration:30, 60 μM
-
Incubation Time:2h
-
Result:Inhibited the activation of c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK)
-
Cell Line:A549 human lung epithelial cell line
-
Concentration:30, 60 μM
-
Incubation Time:
-
Result:Clearly inhibited IL-6 expression in IL-1β-treated lung epithelial cells.
The expression of iNOS was significantly inhibited.
-
Cell Line:A549 human lung epithelial cell line
-
Concentration:30, 60 μM
-
Incubation Time:
-
Result:Clearly inhibited IL-6 expression in IL-1β-treated lung epithelial cells.
The expression of iNOS was significantly inhibited.
-
Cell Line:lipopolysaccharide (LPS)-treated nucleus pulposus cells (NPCs)
-
Concentration:LPS (HY-D1056) 0.5 μg/mL , Moracin M 5-20 μM
-
Incubation Time:24h
-
Result:Effectively inhibited lipopolysaccharide (LPS) -induced inflammatory response, specifically by reducing the increase of inflammatory cytokines IL-1β, TNF-α and IL-6
Inhibited the phosphorylation of PI3K and Akt, promoted the autophagy of NPCs (autophagy) and inhibited the production of inflammatory mediators
Moracin M (20, 60 mg/kg, Oral gavage) alleviates pathological changes in lung tissue in ALI mouse models, including reduces alveolar wall thickness, increases alveolar space, and reduces inflammatory cell infiltration in lung tissue[2].
Moracin M (20, 60 mg/kg, Oral gavage) significantly inhibits NF-κB activation in the lungs in a mouse model of ALI[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:LPS-induced acute lung injury (ALI) mouse models[2]
-
Dosage:LPS (HY-D1056) 2 mg/kg; LPS 2 mg/kg+ Moracin M 20 mg/kg, 60 mg/kg; LPS 2 mg/kg+ Dexamethasone (HY-14648) 30 mg/kg. (n=13)
-
Administration:Oral gavage
-
Result:Reduced the inflammatory response in ALI mouse models and reduced the total number of cells infiltrated in bronchoalveolar lavage (BAL) fluid. The number of neutrophils, macrophages and dendritic cells was significantly decreased.
Reduced the thickness of alveolar wall, increasing alveolar space, and reduced the infiltration of inflammatory cells in lung tissue.
Chemical Information
-
CAS No. 56317-21-6
-
Appearance Solid
-
Masse moléculaire 242.23
-
Formule C14H10O4
-
Color Off-white to light yellow
-
SMILES
OC1=CC(C2=CC3=CC=C(O)C=C3O2)=CC(O)=C1
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
J Agric Food Chem
Comprehensive Quantification of (Poly)phenols in Lotus japonicus with and without Arbuscular Mycorrhizal Symbiosis. [Abstract]2025 Jun 4;73(22):14044-14057. PMID: 40418640 -
Environ Microbiol
Unravelling Wood Extractive Resistance in Phanerochaete chrysosporium Through Random Mutagenesis. [Abstract]2025 Dec;27(12):e70205. PMID: 41342371 -
Arch Dermatol Res
Moracin M promotes hair regeneration through activation of the WNT/β-catenin pathway and angiogenesis. [Abstract]2025 Jan 24;317(1):304. PMID: 39853610
Moracin M purchased from MedChemExpress. Usage Cited in: Arch Dermatol Res. 2025 Jan 24;317(1):304. [Abstract]
The cell viability of human Dermal Papilla Cells (hDPCs) was assessed following treatment with 100 ng/mL of IFN-γ, distinguishing between the anagen and catagen phases. Moracin M at 25 and 50 µM significantly increased cell proliferation.
Moracin M purchased from MedChemExpress. Usage Cited in: Arch Dermatol Res. 2025 Jan 24;317(1):304. [Abstract]
Western blots were performed on Wnt3a, GSK3β, and β-catenin in hDPCs after treatment with Moracin M (12.5, 25, 50 μM) with IFN-γ.
Moracin M purchased from MedChemExpress. Usage Cited in: Arch Dermatol Res. 2025 Jan 24;317(1):304. [Abstract]
The mRNA expression of VEGF gene in hDPCs treated with Moracin M (12.5, 25, 50 μM) with IFN-γ.
-
Solvant et solubilité
DMSO : 100 mg/mL (412.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.67 mg/mL (6.89 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.67 mg/mL (6.89 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Chen SK, et al. Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor. Bioorg Med Chem Lett. 2012 May 1;22(9):3261-4. [Content Brief]
[2]. Lee JH, et al. Moracin M inhibits airway inflammation by interrupting the JNK/c-Jun and NF-κB pathways in vitro and in vivo. Eur J Pharmacol. 2016;783:64-72. [Content Brief]
[3]. Guo F, et al. Moracin M inhibits lipopolysaccharide-induced inflammatory responses in nucleus pulposus cells via regulating PI3K/Akt/mTOR phosphorylation. Int Immunopharmacol. 2018 May;58:80-86. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.1283 mL | 20.6415 mL | 41.2831 mL | 103.2077 mL |
| 5 mM | 0.8257 mL | 4.1283 mL | 8.2566 mL | 20.6415 mL | |
| 10 mM | 0.4128 mL | 2.0642 mL | 4.1283 mL | 10.3208 mL | |
| 15 mM | 0.2752 mL | 1.3761 mL | 2.7522 mL | 6.8805 mL | |
| 20 mM | 0.2064 mL | 1.0321 mL | 2.0642 mL | 5.1604 mL | |
| 25 mM | 0.1651 mL | 0.8257 mL | 1.6513 mL | 4.1283 mL | |
| 30 mM | 0.1376 mL | 0.6881 mL | 1.3761 mL | 3.4403 mL | |
| 40 mM | 0.1032 mL | 0.5160 mL | 1.0321 mL | 2.5802 mL | |
| 50 mM | 0.0826 mL | 0.4128 mL | 0.8257 mL | 2.0642 mL | |
| 60 mM | 0.0688 mL | 0.3440 mL | 0.6881 mL | 1.7201 mL | |
| 80 mM | 0.0516 mL | 0.2580 mL | 0.5160 mL | 1.2901 mL | |
| 100 mM | 0.0413 mL | 0.2064 mL | 0.4128 mL | 1.0321 mL |